Lucid Diagnostics Archives - Medical Design Sourcing

Lucid Diagnostics enrolls first patient in study of esophageal DNA test

Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced today that investigators enrolled the first patient in a stud of its EsoGuard.

Investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center (Cleveland VA) enrolled the patient in a U.S. Defense Dept. (DoD)-funded study of the EsoGuard esophageal DNA test for at-risk patients with gastroesophageal reflux disease (GERD).

Lucid Diagnostics is providing EsoCheck esophageal cell collection devices for the study and will perform EsoGuard testing on the samples collected. Cleveland VA gastroenterologist Dr. Katarina B. Greer serves as the study’s principal investigator.

“We are proud to be partnering with Dr. Greer and the Cleveland VA on this important investigator-initiated clinical study,” Lucid Diagnostics Chairperson and CEO Dr. Lishan Aklog said in a news release. “The study will add important clinical evidence on the impact of EsoGuard in enhancing early detectio…

Pavmed’s Lucid Diagnostics acquires CapNostics and its esophageal cell collection device

Pavmed (NSDQ:PAVM) announced today that its Lucid Diagnostics subsidiary entered into an agreement to buy CapNostics.

Lucid Diagnostics, a wholly-owned subsidiary of Pavmed, entered into a definitive membership interest purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina-based CapNostics, according to a news release.

CapNostics manufactures the FDA-cleared and CE-marked EsophaCap non-endoscopic esophageal cell collection device that has been used in pre-commercial clinical research of esophageal precancer biomarkers at major academic medical centers.

Lucid Diagnostics, which recently publicly filed a registration statement related to a proposed initial public offering (IPO), concurrently entered into an exclusive long-term consulting agreement with Von Dyck, as well as an exclusive long-term manufacturing agreement with the EsophaCap contract manufacturer.

Financial details of the acquisition were not disclosed. Read more

Pavmed subsidiary Lucid Diagnostics files registration statement for IPO

Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced that Lucid publicly filed a registration statement related to a proposed initial public offering (IPO).

The number of shares of common stock and the price range for the offering have not yet been determined, according to a news release. Lucid Diagnostics intends to list its common stock on the Nasdaq market under the “LUCD” ticker.

Cantor Fitzgerald & Co. and Canaccord Genuity LLC will act as joint book-running managers for the proposed offering. BTIG, LLC and Needham & Co., LLC will act as co-lead managers for the proposed offering.

In February of this year, PavMed announced that Lucid would spin off into a separate public company “if favorable market conditions continue to hold, whether it be through an initial public offering (IPO) or a business combination with a healthcare special purpose acquisition corporation.”

At the time of announcing the planned sp…

Lucid Diagnostics gains CE mark for esophageal device

Lucid Diagnostics has received the CE mark for its EsoCheck esophageal cell collection device, its parent company announced today.

EsoCheck is an FDA-cleared, swallowable balloon capsule catheter that enables a clinician to sample surface cells from the esophagus in a less than five-minute, non-invasive office procedure. Lucid touts EsoCheck as the only such device capable of doing so in an anatomically targeted fashion, without sample dilution or contamination.

Get the full story on our sister site, Medical Design & Outsourcing.

PavMed to spin off subsidiary Lucid Diagnostics

Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics will spin off into a separate public company.

In a news release, Pavmed said Lucid Diagnostics intends to spin off if favorable market conditions continue to hold, whether it be through an initial public offering (IPO) or a business combination with a healthcare special purpose acquisition corporation.

Lucid Diagnostics’ board of directors concluded that the move, a long-contemplated step, Pavmed said, will be necessary to help it fulfill its long-term potential as it seeks to unlock its present value and execute on a major new commercial initiative.

Pavmed said in the release that it believes a Lucid spin-off would be in the best interests of the company and its shareholders, while Pavmed will remain Lucid’s largest shareholder following any such transaction.

Lucid’s new commercial initiative is set to accelerate the commercia…